Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Brensocatib demonstrated significant short-term efficacy in reducing exacerbations compared to placebo in the Phase 2 WILLOW trial, with a 42% risk reduction. The Phase 3 ASPEN trial confirmed sustained efficacy over 52 weeks, showing a 19-21% reduction in exacerbation rates. However, the effect size is moderate compared to existing therapies like macrolides, which show larger reductions. Overall, the evidence indicates a clear clinical benefit, but not a transformative one.
Cost effectiveness
The ICER analysis indicates that brensocatib is not cost-effective at the anticipated price of £82,000 per year, with an ICER of approximately £7.5 million per QALY gained. This far exceeds conventional thresholds for cost-effectiveness, suggesting that unless the price is significantly reduced, brensocatib will not be a viable option from an economic perspective.
Quality of life
No significant improvement in quality of life was demonstrated in either the Phase 2 or Phase 3 trials. The QoL-B Respiratory Symptoms score did not show statistically significant changes, indicating that while brensocatib reduces exacerbations, it does not translate into substantial improvements in daily well-being. This lack of demonstrated benefit in HRQoL is a notable gap in the evidence.
Supporting Domains
Safety and Adverse Effects
Brensocatib has a favorable safety profile, with no major safety signals reported in the trials. Adverse events were generally mild to moderate, with skin-related effects being the most notable. The absence of serious adverse events and the overall tolerability of the drug support its use in a chronic setting.
Comparator Selection
The trials appropriately used placebo plus standard care as comparators, reflecting current clinical practice where no approved therapies exist for preventing exacerbations in bronchiectasis. This design allows for clear interpretation of brensocatib’s efficacy against the standard of care.
Patient Population and Subgroups
The trial population was representative of patients with non-CF bronchiectasis who experience frequent exacerbations. Subgroup analyses showed consistent efficacy across various demographics, including adolescents and patients on macrolide therapy, enhancing the generalizability of the results.
Care Pathway Integration
Brensocatib can be integrated into existing care pathways without requiring new diagnostic tests or significant changes in treatment protocols. It is positioned as an add-on therapy for patients with frequent exacerbations, which aligns well with current management strategies.
Resource Use and Cost Implications
The introduction of brensocatib is expected to significantly increase direct medical costs due to its high price, with only modest offsets from reduced exacerbation-related costs. The overall financial burden on healthcare systems is likely to be substantial, raising concerns about its affordability.
Evidence Quality and Robustness
The evidence is based on high-quality randomized controlled trials with large sample sizes and rigorous methodologies. Both Phase 2 and Phase 3 trials were well-conducted, with consistent results supporting the efficacy and safety of brensocatib.
Uncertainty, Sensitivity, and Broader Impacts
There are uncertainties regarding long-term efficacy and cost-effectiveness, particularly related to the drug’s pricing and its impact on healthcare utilization. While the immediate evidence is strong, the broader implications for access and equity remain to be fully understood.
